Addresses 1
This report describes a rare case of a patient with increased urinary dopamine excretion in association with bilateral carotid body tumours. Excretion of adrenaline, noradrenaline, metadrenaline, normetadrenaline and 4-hydroxy-3-methoxymandelic acid (HMMA) were within the reference ranges, and an 123 I-meta-iodobenzylguanidine (MIBG) scan showed uptake in the neck masses, with no other abnormal uptake anywhere else in the body. The patient is being managed conservatively as the tumours are not amenable to resection on account of their size and vascularity. There are only four previous case reports of dopamine-secreting tumours of the carotid body described in the literature, all of whom were women. The tumours were unilateral in three cases and bilateral in the fourth case. Familial cases of carotid body tumours have a higher prevalence of bilateral tumours than nonfamilial cases. Recent reports in the literature have suggested that a significant number of patients with extra-adrenal catecholamine-secreting paragangliomas have a genetic mutation in one of the identified susceptibility genes for catecholamine-secreting tumours, despite having no other affected family members, and a mutation has been found in the succinate dehydrogenase gene for this patient. 
Case report
A 61-year-old gentleman with a long-standing history of hypertension presented with syncopal episodes to the casualty department in December 1999. The initial diagnosis was thought to be recurrent transient ischaemic attacks in association with bilateral carotid bruits. Following a neck ultrasound scan, carotid angiography revealed bilateral large carotid body tumours encircling each common carotid artery with splaying of the internal and external carotid arteries; a characteristic benign tumour blush was seen (Figure1). The masses in the neck ( Figure 2 ) were ¢rst commented on by an Ear, Nose and Throat (ENT) surgeon when the patient underwent a tonsillectomy 20 years ago to alleviate sleep apnoea. Due to recurrence of this problem, a trachaeostomy was carried out, and due to episodes of collapse ascribed to asystole as a result of carotid sinus baroreceptor hypersensitivity secondary to his carotid body tumours, a permanent pacemaker was inserted. 1 Although these interventions brought about signi¢cant improvement in the clinical condition of the patient, his blood pressure and heart rate showed large variations on 24 h monitoring (70/41--219/102 mmHg, 14--98 bpm). The patient is not currently receiving any medical management for his labile hypertension.
Baseline laboratory investigations were normal (urea ¼ 7.2 mmol/L, creatinine ¼ 93 mmol/L, calcium ¼ 2.20 mmol/L, albumin ¼ 38 g/L). As his blood pressure remained labile, urinary catecholamines were requested. Dopamine excretion was signi¢cantly elevated at 20,679 nmol/24 h (upper limit of reference range 4440 nmol/24 h); excretion of the dopamine metabolite homovanillic acid (HVA) was also increased at 13.1mmol/mol creatinine (upper limit of reference range 5 mmol/mol creatinine). Excretion of noradrenaline, adrenaline, normetadrenaline, metadrenaline and 4-hydroxy-3-methoxymandelic acid (HMMA) were all within the reference ranges (Table 1) . 123 I-meta-iodobenzylguanidine (MIBG) scintigraphy showed faint uptake in the tumours in the neck, with no other pathological uptake identi¢ed ( Figure 3 ). Molecular analysis of the patient's DNA has identi-¢ed a heterozygous mutation (724C4T) in exon 7 of the succinate dehydrogenase B subunit (SDHB) gene, resulting in a mutation in amino acid 242 from arginine to cysteine. No mutations were reported in the D subunit (SDHD) gene. Sequence analysis of exons 1, 2 and 3 of the Von Hippel--Lindau (VHL) gene has shown no evidence of a mutation, deletion or duplication.
The patient has not identi¢ed any other family history for catecholamine-secreting tumours.
Discussion
The patient is unusual on account of his having bilateral dopamine-secreting carotid body tumours which are not amenable to surgical resection on account of their size and vascularity, and the otherwise high anaesthetic risk of the patient. He has declined radiotherapy. With regard to the medical management of this patient, it is well recognized that dopamine antagonists such as sulpiride, metoclopramide and domperidone are potentially harmful because of the risk of hypertensive crises in patients with catecholaminesecreting tumours. 2 The episodes of syncope and collapse attributed to asystole and ameliorated by the insertion of a pacemaker may have also been related to hypotension, as a result of dopamine secretion by the tumours in his neck. 3 Carotid body tumours are composed of the paraganglionic cells and sustentacular cells, which have chemoreceptor activity. Alternative terms such as chemodectomas or glomus tumours have been used but the term 'paragangliomas' to describe such tumours is preferred. Paragangliomas arise from embryonic neural crest derivates, which could be sympathetic (thoracic, abdominal, Zuckerkandl body at the aortic bifurcation or adrenal medullary) or parasympathetic (carotid body, intravagal, aortopulmonary or jugulotympanic). The more familiar term 'phaeochromocytoma' applies to catecholamine-secreting paragangliomas arising in the adrenal medulla.
Carotid body tumours have been associated with secretion of noradrenaline, normetadrenaline or dopamine, but the majority of tumours are not catecholamine-secreting. 3 Three cases of dopaminesecreting carotid body tumours already described in the literature 3--5 were only on one side of the neck only and were successfully treated by surgery. Two of the cases 3,4 were of malignant dopamine-secreting tumours in two women (aged 23 and 40 years), while the third case, in a woman aged 76, 5 was reported to be benign; however, the patient was only followed up for one year and the diagnosis of malignant paraganglioma is heavily based on the presence of metastatic lesions, which are likely to be dependent on the extent of the follow-up period. Righini et al. 6 reported the fourth case, a woman aged 53 with bilateral dopamine-secreting carotid body tumours, who underwent complete resection successively. She subsequently presented with metastases two years later.
In some laboratories, urinary dopamine results are not routinely reported for adult samples referred for the investigation of catecholamine-secreting tumours, subsequent to recommendations published in the Annals of Clinical Biochemistry in 1993. 7 In their study of 20 patients with histologically proven phaeochromocytomas, Graham et al. 7 state that dopamine is an insensitive marker and that exclusively dopaminesecreting tumours are rare. Their results showed that the diagnostic sensitivity for urinary dopamine was only 10%, compared with 70% for urinary noradrenaline and 50% for urinary adrenaline. In a separate study of 50 cases, 8 the sensitivity of urinary dopamine was reported to be 66%, similar to that of urinary adrenaline at 64%, again with the sensitivity of urinary noradrenaline much higher at 93%. One possible explanation for the poor performance of urinary dopamine could be the dependence of urinary dopamine levels on renal function. In patients with chronic renal disease, urinary dopamine excretion is mainly under the in£uence of the glomerular ¢ltration rate, irrespective of the underlying pathology, and urinary dopamine excretion correlates signi¢cantly with creatinine clearance. 9 Another reason for measuring urinary dopamine levels is that high urinary dopamine excretion can be used to di¡erentiate between malignant and Figure 3 123 I-meta-iodobenzylguanidine (MIBG) scan showing uptake in the masses in the neck benign phaeochromocytomas. High preoperative 24 h urinary dopamine levels, extra-adrenal tumour location, high tumour weight, elevated tumour dopamine concentration and postoperative persistent arterial hypertension are all factors that increase the likelihood of malignant phaeochromocytoma. 10, 11 Adherence to the recommendation to only report results for urinary noradrenaline and adrenaline resulted in di⁄culty in reaching a diagnosis for our patient because the dopamine excretion was ¢rst measured in 1998 but not noted to be signi¢cantly high until almost two years later. It has been suggested that 3-methoxytyramine may also be a useful diagnostic and monitoring parameter for catecholamine-secreting carotid body tumours. 12 In one study of 923 patients with carotid body tumours, 13 31.8% of patients with familial carotid body tumours (n ¼ 88) had bilateral lesions, as opposed to 4.4% of the non-familial cases.
A more recent publication 14 has shown that when an extra-adrenal catecholamine-secreting tumour is found either in isolation or with an adrenal phaeochromocytoma, the molecular di¡erential diagnosis includes mutations of the gene for subunits B and D of succinate dehydrogenase (SDHB and SDHD) and the tumour suppressor gene associated with von Hippel--Lindau disease (VHL), but not with mutations of the proto-oncogene RET, associated with multiple endocrine neoplasia type 2 (MEN-2). In their study of 271 patients with catecholamine-secreting tumours but no family history at diagnosis, Neumann et al. 14 reported 30 patients with extra-adrenal tumours, of whom14 (47%) were found to have a mutation in either SDHB (n ¼ 6), SDHD (n ¼ 4), or VHL (n ¼ 4). About 20% of their cases of adrenal phaeochromocytoma did have RET mutations, however, and it is important to do RET mutation analysis in patients with adrenal disease, particularly those patients who also have raised levels of plasma thyrocalcitonin. Clinical clues pointing to the presence of a hereditary syndrome include multifocal or extra-adrenal tumours and a young age at presentation. Unusually, none of the patients with a mutation in SDHB had multifocal tumours, and nine out of the 23 patients with mutations in SDHD or SDHB presented after the age of 30 years. In another study of 84 cases of apparently sporadic phaeochromocytomas, Gimenez-Roqueplo et al. 15 found that germ-line mutations in the SDHB gene but not SDHD gene were strongly associated with extra-adrenal phaeochromocytomas and conferred a high risk of recurrence or malignancy.
The SDHD gene defect is thought to be imprinted such that the expression of the gene is determined by the sex of the transmitting parent, and children are a¡ected only when they receive the gene from their father. The gene defect can be carried by women for several generations before being transmitted by a man. 16 In contrast, both maternal and paternal inheritance of SDHB mutations has been reported. 17 The mutation in the SDHB gene reported for our patient,724C4T (Arg242Cys), has been previously reported for a female patient with a unilateral glomus vagale tumour and no family history, but the pathogenicity of this mutation has not yet been established. 18 It is possible that this variant could be a normal polymorphism of the gene, although subunits SDHA and SDHB of succinate dehydrogenase (mitochondrial complex II) form the hydrophilic catalytic part of the complex and are highly conserved.
The possibility of a catecholamine-secreting tumour should be investigated in patients with carotid body masses and labile blood pressure for the following reasons: ¢rstly, if high catecholamine excretion is detected, this could be used as a tumour marker to monitor the patient for recurrent disease following surgical resection, 19 or possibly to follow progression of the disease, as in the inoperable case of our patient; and secondly, if the patient is shown to carry one of the genetic mutations described above, measurement of catecholamine excretion would be a simple and relatively inexpensive method to screen other family members for the disease --a similar form of monitoring to that used to screen patients with a family history of MEN.
